Table 6: Individual study methodology characteristics.
| Study | N | Adequate randomization methods |
Baseline comparable |
Adequate Allocation Concealment |
Blinding of outcome assessors |
Sample Size Calculation |
Losses to †FU (%) |
#ITT |
|---|---|---|---|---|---|---|---|---|
| Rao 2007 |
112 | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
| Bruggink 2007 |
112 | ✓ | *†Except for gender | ✓ | ✓ | ✓ | 0 | ✓ |
| Wierzchowiecki 2006 |
160 | ✓ | ✓ | Unclear | Not reported | Not reported | Not reported | Not reported |
| Mejhert 2004 |
208 | ✓ | ✓ | $✓ | ¶No | ✓ | 0 | ✓ |
| Stromberg 2003 |
106 | ✓ | * Except for the number of persons with hypertension and ‡†diabetes | ✓ | ✓ | ✓ | 0 | ✓ |
| Doughty 2002 |
197 | ✓ | ✓ | Unclear | ✓ | ✓ | 0.9 | ✓ |
| Dunagan 2005 |
151 | ✓ | *† Except for mean ACE inhibitor dose | Unclear | ✓ | ✓ | 0.9 | ✓ |
| GESICA 2005 |
1518 | ✓ | ✓ | ✓ | ✓ | ✓ | 0 | ✓ |
*
Significantly higher proportion or dose in treatment group
†
Adjusted analysis for baseline differences did not change results
‡
Significantly higher proportion in the control group
¶
Primary end-point was patient self administered Quality of life questionnaire
#
ITT is intention to treat analysis
$
Adequate allocation concealment methods confirmed by author